ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2.
Our clinical development program is focused on a Phase 2a clinical trial combining Aileron’s lead product candidate ALRN-6924 and Pfizer’s palbociclib (IBRANCE®), for the treatment of patients with MDM2-amplified cancers, and a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Our first myelopreservation clinical trial is in small cell lung cancer patients treated with the chemotherapy topotecan.
ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of cancers and for the purpose of testing ALRN-6924 as a therapeutic agent that can protect cancer patients from chemotherapeutic toxicities (“Myelopreservation Trial”). Preliminary clinical results have demonstrated a favorable safety profile and evidence of durable antitumor activity.
Our ongoing clinical trials of ALRN-6924 include:
Past clinical trials of ALRN-6924:
For more information, access our ongoing trial updates at ClinicalTrials.gov.